Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6103
- Registration Number
- NCT01243424
- Locations
- 🇺🇸
PMI Health Research Group, Atlanta, Georgia, United States
🇺🇸North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Matrix Research Institute, Tustin, California, United States
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
- Conditions
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 480
- Registration Number
- NCT01189890
START-J: SiTAgliptin in eldeRly Trial in Japan
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2017-04-14
- Target Recruit Count
- 305
- Registration Number
- NCT01183104
- Locations
- 🇯🇵
Japan Association for Diabetes Education and Care, Chiyoda-Ku, Tokyo, Japan
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
- Conditions
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 380
- Registration Number
- NCT01177384
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1549
- Registration Number
- NCT01167881
- Locations
- 🇦🇹
1245.28.43003 Boehringer Ingelheim Investigational Site, Wien, Austria
🇺🇸1245.28.10030 Boehringer Ingelheim Investigational Site, Draper, Utah, United States
🇺🇸1245.28.10014 Boehringer Ingelheim Investigational Site, Rochester, New York, United States
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 521
- Registration Number
- NCT01123980
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 241
- Registration Number
- NCT01087502
- Locations
- 🇦🇺
1218.64.61002 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia
🇨🇦1218.64.20007 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
🇨🇦1218.64.20008 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
- Conditions
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 810
- Registration Number
- NCT01075282
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2010-01-21
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 44
- Registration Number
- NCT01052909
- Locations
- 🇨🇦
Anapharm Inc, Sainte-Foy, Quebec, Canada
Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin
- First Posted Date
- 2009-11-03
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 957
- Registration Number
- NCT01006603
- Locations
- 🇬🇧
Research Site, Wellingborough, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.